Cargando…

Neurodegeneration and Neuroprotection in Glaucoma

Glaucoma is the principal cause of irreversible blindness in the world. The disease leads to progressive optic nerve degeneration with a gradual loss of retinal ganglion cells. Neurodegeneration in glaucoma extends beyond the eye into the lateral geniculate nucleus and visual cortex, and the disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauthier, Angela C., Liu, Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: YJBM 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797839/
https://www.ncbi.nlm.nih.gov/pubmed/27505018
_version_ 1782422035916390400
author Gauthier, Angela C.
Liu, Ji
author_facet Gauthier, Angela C.
Liu, Ji
author_sort Gauthier, Angela C.
collection PubMed
description Glaucoma is the principal cause of irreversible blindness in the world. The disease leads to progressive optic nerve degeneration with a gradual loss of retinal ganglion cells. Neurodegeneration in glaucoma extends beyond the eye into the lateral geniculate nucleus and visual cortex, and the disease even shares some characteristics with other central nervous system degenerative disorders. Glaucoma destroys neurons through oxidative stress, impairment in axonal transport, neuroinflammation, and excitotoxicity. Autophagy may promote or inhibit disease progression. Currently, lowering intraocular pressure is the only way proven to delay glaucoma advancement. However, many new therapies are being developed, including antioxidants, adenosine receptor antagonists, Rho-pathway inhibitors, stem cell therapy, and neurotrophic factors. These therapies focus on neuroprotection, and they may eventually halt glaucoma progression or reverse the process of the disease itself.
format Online
Article
Text
id pubmed-4797839
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher YJBM
record_format MEDLINE/PubMed
spelling pubmed-47978392016-03-30 Neurodegeneration and Neuroprotection in Glaucoma Gauthier, Angela C. Liu, Ji Yale J Biol Med Review Glaucoma is the principal cause of irreversible blindness in the world. The disease leads to progressive optic nerve degeneration with a gradual loss of retinal ganglion cells. Neurodegeneration in glaucoma extends beyond the eye into the lateral geniculate nucleus and visual cortex, and the disease even shares some characteristics with other central nervous system degenerative disorders. Glaucoma destroys neurons through oxidative stress, impairment in axonal transport, neuroinflammation, and excitotoxicity. Autophagy may promote or inhibit disease progression. Currently, lowering intraocular pressure is the only way proven to delay glaucoma advancement. However, many new therapies are being developed, including antioxidants, adenosine receptor antagonists, Rho-pathway inhibitors, stem cell therapy, and neurotrophic factors. These therapies focus on neuroprotection, and they may eventually halt glaucoma progression or reverse the process of the disease itself. YJBM 2016-03-24 /pmc/articles/PMC4797839/ /pubmed/27505018 Text en Copyright ©2016, Yale Journal of Biology and Medicine https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons CC BY-NC license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use the material for commercial purposes.
spellingShingle Review
Gauthier, Angela C.
Liu, Ji
Neurodegeneration and Neuroprotection in Glaucoma
title Neurodegeneration and Neuroprotection in Glaucoma
title_full Neurodegeneration and Neuroprotection in Glaucoma
title_fullStr Neurodegeneration and Neuroprotection in Glaucoma
title_full_unstemmed Neurodegeneration and Neuroprotection in Glaucoma
title_short Neurodegeneration and Neuroprotection in Glaucoma
title_sort neurodegeneration and neuroprotection in glaucoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797839/
https://www.ncbi.nlm.nih.gov/pubmed/27505018
work_keys_str_mv AT gauthierangelac neurodegenerationandneuroprotectioninglaucoma
AT liuji neurodegenerationandneuroprotectioninglaucoma